- Home
- DIBS vs ADVM Comparison
DIBS vs ADVM Comparison
Compare DIBS & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DIBS
- ADVM
- Stock Information
- Founded
- DIBS 2000
- ADVM 2006
- Country
- DIBS United States
- ADVM United States
- Employees
- DIBS N/A
- ADVM N/A
- Industry
- DIBS Catalog/Specialty Distribution
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DIBS Consumer Discretionary
- ADVM Health Care
- Exchange
- DIBS Nasdaq
- ADVM Nasdaq
- Market Cap
- DIBS 99.7M
- ADVM 94.6M
- IPO Year
- DIBS 2021
- ADVM 2014
- Fundamental
- Price
- DIBS $3.89
- ADVM $4.20
- Analyst Decision
- DIBS Hold
- ADVM Buy
- Analyst Count
- DIBS 1
- ADVM 5
- Target Price
- DIBS N/A
- ADVM $16.60
- AVG Volume (30 Days)
- DIBS 75.7K
- ADVM 992.9K
- Earning Date
- DIBS 11-07-2025
- ADVM 11-07-2025
- Dividend Yield
- DIBS N/A
- ADVM N/A
- EPS Growth
- DIBS N/A
- ADVM N/A
- EPS
- DIBS N/A
- ADVM N/A
- Revenue
- DIBS $88,640,000.00
- ADVM $1,000,000.00
- Revenue This Year
- DIBS $2.87
- ADVM $1,449.40
- Revenue Next Year
- DIBS $3.26
- ADVM N/A
- P/E Ratio
- DIBS N/A
- ADVM N/A
- Revenue Growth
- DIBS 3.21
- ADVM N/A
- 52 Week Low
- DIBS $2.30
- ADVM $1.78
- 52 Week High
- DIBS $4.39
- ADVM $8.20
- Technical
- Relative Strength Index (RSI)
- DIBS 89.07
- ADVM 48.02
- Support Level
- DIBS $2.55
- ADVM $3.98
- Resistance Level
- DIBS $4.10
- ADVM $4.28
- Average True Range (ATR)
- DIBS 0.18
- ADVM 0.38
- MACD
- DIBS 0.13
- ADVM -0.10
- Stochastic Oscillator
- DIBS 87.74
- ADVM 14.52
About DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The Company has a single reportable and operating segment that contains one reporting unit, which consists of the Company's online marketplace that enables commerce between sellers and buyers. The company generates maximum revenue from fees from seller marketplace services and other services, including advertisements.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.